BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 37537590)

  • 1. Predicting delayed methotrexate elimination in pediatric acute lymphoblastic leukemia patients: an innovative web-based machine learning tool developed through a multicenter, retrospective analysis.
    Jian C; Chen S; Wang Z; Zhou Y; Zhang Y; Li Z; Jian J; Wang T; Xiang T; Wang X; Jia Y; Wang H; Gong J
    BMC Med Inform Decis Mak; 2023 Aug; 23(1):148. PubMed ID: 37537590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia: A Danish population-based study.
    Schmidt D; Kristensen K; Schroeder H; Wehner PS; Rosthøj S; Heldrup J; Damsgaard L; Schmiegelow K; Mikkelsen TS
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27637. PubMed ID: 30835935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma.
    Nakano T; Kobayashi R; Matsushima S; Hori D; Yanagi M; Suzuki D; Kobayashi K
    Int J Hematol; 2021 May; 113(5):744-750. PubMed ID: 33389654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Creatinine clearance rate and serum creatinine concentration are related to delayed methotrexate elimination in children with lymphoblastic malignancies.
    Mao J; Zhang L; Shen H; Tang Y; Song H; Zhao F; Xu W
    Neoplasma; 2014; 61(1):77-82. PubMed ID: 24195512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical application of the simultaneous detection of methotrexate and 7-hydroxymethotrexate in the delayed elimination for pediatric acute lymphoblastic leukemia].
    Luo GJ; Wang L; Hu GF; Li CB; Liu HX; Peng MT
    Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(25):1973-1978. PubMed ID: 32629599
    [No Abstract]   [Full Text] [Related]  

  • 6. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).
    Skärby T; Jönsson P; Hjorth L; Behrentz M; Björk O; Forestier E; Jarfelt M; Lönnerholm G; Höglund P
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):311-20. PubMed ID: 12721759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies.
    Xu WQ; Zhang LY; Chen XY; Pan BH; Mao JQ; Song H; Li JY; Tang YM
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):79-86. PubMed ID: 24158402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel and replicated clinical and genetic risk factors for toxicity from high-dose methotrexate in pediatric acute lymphoblastic leukemia.
    Zobeck M; Bernhardt MB; Kamdar KY; Rabin KR; Lupo PJ; Scheurer ME
    Pharmacotherapy; 2023 Mar; 43(3):205-214. PubMed ID: 36764694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
    Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia: Predictors of Delayed Clearance and the Effect of Increased Hydration Rate on Methotrexate Clearance.
    Chen AR; Wang YM; Lin M; Kuo DJ
    Cureus; 2020 Jun; 12(6):e8674. PubMed ID: 32699674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate.
    Rask C; Albertioni F; Schrøder H; Peterson C
    Pediatr Hematol Oncol; 1996; 13(4):359-67. PubMed ID: 8837142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
    Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of
    Yang FF; Xue TL; Gao C; Wu Y; Lin W; Li J; Zhang RD; Zheng HY; Liu SG
    Pharmacogenomics; 2022 Oct; 23(15):821-834. PubMed ID: 36193736
    [No Abstract]   [Full Text] [Related]  

  • 14. Low Serum Albumin Level Is a Risk Factor for Delayed Methotrexate Elimination in High-Dose Methotrexate Treatment.
    Kataoka T; Sakurashita H; Kajikawa K; Saeki Y; Taogoshi T; Matsuo H
    Ann Pharmacother; 2021 Oct; 55(10):1195-1202. PubMed ID: 33543634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy, side effects and blood concentration monitoring of high-dose methotrexate in treatment of 180 children with acute lymphoblastic leukemia].
    Wang H; Chi ZF; Li S; Wang XL; Hao LC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):949-52. PubMed ID: 21867621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethnic-specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high-dose methotrexate.
    Harris RD; Bernhardt MB; Zobeck MC; Taylor OA; Gramatges MM; Schafer ES; Lupo PJ; Rabin KR; Scheurer ME; Brown AL
    Cancer; 2023 Apr; 129(8):1287-1294. PubMed ID: 36692972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Machine learning to predict high-dose methotrexate-related neutropenia and fever in children with B-cell acute lymphoblastic leukemia.
    Zhan M; Chen ZB; Ding CC; Qu Q; Wang GQ; Liu S; Wen FQ
    Leuk Lymphoma; 2021 Oct; 62(10):2502-2513. PubMed ID: 33899650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral mucositis in childhood cancer patients receiving high-dose methotrexate: Prevalence, relationship with other toxicities and methotrexate elimination.
    Valer JB; Curra M; Gabriel AF; Schmidt TR; Ferreira MBC; Roesler R; Evangelista JMC; Martins MAT; Gregianin L; Martins MD
    Int J Paediatr Dent; 2021 Mar; 31(2):238-246. PubMed ID: 32815183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
    Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
    Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia.
    Medellin-Garibay SE; Hernández-Villa N; Correa-González LC; Morales-Barragán MN; Valero-Rivera KP; Reséndiz-Galván JE; Ortiz-Zamudio JJ; Milán-Segovia RDC; Romano-Moreno S
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):21-31. PubMed ID: 31673826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.